Sutro Biopharma, Inc. (STRO) Analysts See $-0.65 EPS; Sorrento Therapeutics (SRNE)’s Sentiment Is 1.15

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Logo

Analysts expect Sutro Biopharma, Inc. (NASDAQ:STRO) to report $-0.65 EPS on February, 13.After having $-21.26 EPS previously, Sutro Biopharma, Inc.’s analysts see -96.94% EPS growth. The stock decreased 4.39% or $0.47 during the last trading session, reaching $10.35. About 44,998 shares traded. Sutro Biopharma, Inc. (NASDAQ:STRO) has 0.00% since January 14, 2018 and is . It has by 0.00% the S&P500.

Sorrento Therapeutics Inc (SRNE) investors sentiment decreased to 1.15 in Q3 2018. It’s down -1.27, from 2.42 in 2018Q2. The ratio has dropped, as 38 investment managers increased or started new positions, while 33 sold and decreased their positions in Sorrento Therapeutics Inc. The investment managers in our database now have: 31.19 million shares, up from 28.15 million shares in 2018Q2. Also, the number of investment managers holding Sorrento Therapeutics Inc in top ten positions decreased from 1 to 0 for a decrease of 1. Sold All: 12 Reduced: 21 Increased: 23 New Position: 15.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. The company has market cap of $236.37 million. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. It currently has negative earnings. The company's product candidates include STRO-001, an antibody-drug conjugate directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.

More notable recent Sorrento Therapeutics, Inc. (NASDAQ:SRNE) news were published by: Nasdaq.com which released: “Dr. Henry Ji to Participate In Financing Expert Panel at East/West CEO Conference – Nasdaq” on January 04, 2019, also Finance.Yahoo.com with their article: “The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial – Yahoo! Finance News” published on December 21, 2018, Benzinga.com published: “22 Stocks Moving In Wednesday’s Pre-Market Session – Benzinga” on December 19, 2018. More interesting news about Sorrento Therapeutics, Inc. (NASDAQ:SRNE) were released by: Seekingalpha.com and their article: “Sorrento secures $150M in debt financing – Seeking Alpha” published on November 08, 2018 as well as Nasdaq.com‘s news article titled: “Analysts Estimate Sorrento Therapeutics (SRNE) to Report a Decline in Earnings: What to Look Out for – Nasdaq” with publication date: November 01, 2018.

Since January 1, 0001, it had 0 buys, and 1 sale for $1.49 million activity.

The stock decreased 3.64% or $0.09 during the last trading session, reaching $2.38. About 511,778 shares traded. Sorrento Therapeutics, Inc. (SRNE) has risen 29.78% since January 14, 2018 and is uptrending. It has outperformed by 29.78% the S&P500. Some Historical SRNE News: 28/03/2018 – Sorrento Therapeutics Chairman/CEO update to stockholders; 11/05/2018 – Consolidated Research: 2018 Summary Expectations for Sunstone Hotel Investors, Plains All American Pipeline, Sorrento Therapeut; 21/03/2018 – CUSO Financial Services and Sorrento Pacific Financial Receive Fifth Consecutive Tech Innovation Award at Bank Insurance &; 22/04/2018 – DJ Sorrento Therapeutics Inc, Inst Holders, 1Q 2018 (SRNE); 21/03/2018 – CUSO Financial Services and Sorrento Pacific Financial Receive Fifth Consecutive Tech Innovation Award at Bank Insurance & Securities Association Annual Conference; 27/03/2018 – CUSO Financial Services and Sorrento Pacific Financial Executive Daniel Kilroy Named CFO of The Year by San Diego Business; 27/03/2018 – SORRENTO THERAPEUTICS REPORTS UNSECURED $120.5M CONV NOTE FINAN; 27/03/2018 – SORRENTO THERAPEUTICS ANNOUNCES UNSECURED $120.5M CONVERTIBLE NOTE FINANCING; 13/04/2018 – President of Spectrum Global Solutions lnterviewed on RedChip Money Report; 14/03/2018 – Glancy Prongay & Murray LLP Commences Investigation on Behalf of Sorrento Therapeutics, Inc. Investors (SRNE)

Wildcat Capital Management Llc holds 1.41% of its portfolio in Sorrento Therapeutics, Inc. for 415,765 shares. Vident Investment Advisory Llc owns 320,492 shares or 0.06% of their US portfolio. Moreover, A.R.T. Advisors Llc has 0.04% invested in the company for 186,918 shares. The New York-based Matrix Asset Advisors Inc Ny has invested 0.04% in the stock. Hrt Financial Llc, a New York-based fund reported 44,931 shares.

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.